This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boekstegers, P. Articles by Steinbeck, G. Search for Related Content PubMed PubMed Citation Articles by Boekstegers, P. Articles by Steinbeck, G.

CLINICAL STUDY: HYPERTROPHIC CARDIOMYOPATHY

Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy

^a Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

Manuscript received August 28, 2000; revised manuscript received April 23, 2001, accepted May 15, 2001.

Reprint requests and correspondence: Dr. Peter Boekstegers, Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, 81366 Munich, Germany
boekstegers{at}med1.med.uni-muenchen.de

OBJECTIVES

We sought to assess the safety and efficacy of pressure-guided nonsurgical myocardial reduction (NSMR) with the induction of small septal infarctions in patients with hypertrophic obstructive cardiomyopathy (HOCM).

BACKGROUND

Nonsurgical myocardial reduction has been shown to decrease left ventricular outflow tract (LVOT) obstruction and to improve symptoms in patients with HOCM. Infarct sizes differ considerably among studies published so far.

METHODS

In 50 patients, the LVOT gradient was invasively determined at the time of the intervention, four to six months (n = 49) and 12 to18 months (n = 25) after NSMR. New York Heart Association functional class and quality of life were assessed by using a standard questionnaire. Exercise capacity was tested by spiro-ergometry. Left ventricular (LV) mass was determined by electron beam computed tomography.

RESULTS

Small septal infarctions (mean creatine kinase value 413 ± 193 U/l) resulted in a sustained decrease in LVOT gradients, from 80 ± 33 to 18 ± 17 mm Hg after four to six months (p < 0.001, n = 49) and to 17 ± 15 mm Hg (p < 0.001, n = 25) after 12 to 18 months. Nonsurgical myocardial reduction was followed by a decrease in LV hypertrophy, which was associated with a sustained increase in exercise capacity, as well as improvement in quality of life.

CONCLUSIONS

Pressure-guided NSMR inducing small septal infarctions was sufficient to result in a sustained decrease in LVOT obstruction and to improve symptoms. The incidence of complications, such as complete heart block with necessary permanent pacemaker implantation (<10%), seems to be diminished by minimizing the infarct size.

Abbreviations and Acronyms   ANOVA = analysis of variance   CK = creatine kinase   HOCM = hypertrophic obstructive cardiomyopathy   LV = left ventricle, left ventricular   LVEDP = left ventricular end-diastolic pressure   LVH = left ventricular hypertrophy   LVOT = left ventricular outflow tract   NSMR = nonsurgical myocardial reduction   NYHA = New York Heart Association

This article has been cited by other articles:

				S. K. Dhar, V. Varadharajan, A. Al-Mohammad, J. Sandoval, and E. D Grech Symptomatic hypertrophic obstructive cardiomyopathy: semi-supine bicycle ergometry as a useful provocative manoeuvre to elicit latent gradient BMJ Case Reports, March 30, 2009; 2009(mar30_1): bcr1020081044 - bcr1020081044. [Abstract] [Full Text]

				P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF]

				W. G. van Dockum, A. M. Beek, F. J. ten Cate, J. M. ten Berg, O. Bondarenko, M. J.W. Gotte, J. W.R. Twisk, M. B.M. Hofman, C. A. Visser, and A. C. van Rossum Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Circulation, May 17, 2005; 111(19): 2503 - 2508. [Abstract] [Full Text] [PDF]

				B. J. Maron, J. A. Dearani, S. R. Ommen, M. S. Maron, H. V. Schaff, B. J. Gersh, and R. A. Nishimura The case for surgery in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2044 - 2053. [Abstract] [Full Text] [PDF]

				F H Gietzen, C J Leuner, L Obergassel, C Strunk-Mueller, and H Kuhn Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients Heart, June 1, 2004; 90(6): 638 - 644. [Abstract] [Full Text] [PDF]

				C. D. Kimmelstiel and B. J. Maron Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Circulation, February 3, 2004; 109(4): 452 - 456. [Full Text] [PDF]

				B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]

				Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]

				S. M. Chang, S. F. Nagueh, W. H. Spencer III, and N. M. Lakkis Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy J. Am. Coll. Cardiol., July 16, 2003; 42(2): 296 - 300. [Abstract] [Full Text] [PDF]

				F. H. Gietzen, C. J. Leuner, L. Obergassel, C. Strunk-Mueller, and H. Kuhn Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions Circulation, July 23, 2002; 106(4): 454 - 459. [Abstract] [Full Text] [PDF]